Aircastle Ltd. (AYR) Jumps 5.4% on February 22

Equities Staff |

Aircastle Ltd. (AYR) was among the biggest gainers on the Russell 2000 for Monday February 22 as the stock popped 5.4% to $19.34, representing a gain of $0.99 per share. Some 409,080 shares traded hands on 3,438 trades, compared with an average daily volume of 569,381 shares out of a total float of 78.56 million. The stock opened at $18.64 and traded with an intraday range of $19.57 to $18.60.

After today's gains, Aircastle Ltd. reached a market cap of $1.52 billion. Aircastle Ltd. has had a trading range between $25.52 and $15.06 over the last year, and it had a 50-day SMA of $18.85 and a 200-day SMA of $21.12.

The stock has a P/E Ratio of 12.2.

Aircastle Ltd is a holding company. The Company through its subsidiaries is engaged in investing in aviation assets, including acquiring, leasing, managing and selling high-utility commercial jet aircraft.

Aircastle Ltd. is based out of Stamford, CT and has some 103 employees. Its CEO is Ron Wainshal.

For a complete fundamental analysis analysis of Aircastle Ltd., check out’s Stock Valuation Analysis report for AYR. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


D-Wave Systems is the first quantum computing company. Its mission is to integrate new discoveries in physics, engineering, manufacturing, and computer science into breakthrough approaches to computation to help solve…

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…